CN Patent

CN120040429B — 一种取代四氢呋喃衍生物的结晶形式及其用途

Assigned to Shandong Shengdi Pharmaceutical Co ltd · Expires 2026-03-31 · 0y expired

What this patent protects

本公开涉及一种取代四氢呋喃衍生物的结晶形式及其用途。具体而言，本公开提供(2R,3S,4S,5R)‑3‑(3,4‑二氟‑2‑甲氧基苯基)‑N‑(2‑((Z)‑(N’‑羟基甲脒基)吡啶‑4‑基)‑4,5‑二甲基‑5‑(三氟甲基)四氢呋喃‑2‑甲酰胺的晶型A、晶型B、晶型C，其具备良好的稳定性，可更好地用于临床治疗。

USPTO Abstract

本公开涉及一种取代四氢呋喃衍生物的结晶形式及其用途。具体而言，本公开提供(2R,3S,4S,5R)‑3‑(3,4‑二氟‑2‑甲氧基苯基)‑N‑(2‑((Z)‑(N’‑羟基甲脒基)吡啶‑4‑基)‑4,5‑二甲基‑5‑(三氟甲基)四氢呋喃‑2‑甲酰胺的晶型A、晶型B、晶型C，其具备良好的稳定性，可更好地用于临床治疗。

Drugs covered by this patent

Patent Metadata

Patent number
CN120040429B
Jurisdiction
CN
Classification
—
Expires
2026-03-31
Drug substance claim
No
Drug product claim
No
Assignee
Shandong Shengdi Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.